Regenxbio is pricing 10 million common shares at $9 each, alongside 1.1 million pre-funded warrants also set at the $9 mark. The capital raise, managed by joint bookrunners Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho, is slated to close on July 20. Underwriters maintain a 30-day window to purchase an additional 1.7 million shares to cover potential over-allotments.
Regenxbio Slides 13% After Announcing $100 Million Stock Offering
Investors sent Regenxbio shares tumbling 13% to $9.69 on Friday morning, following the biotechnology firm’s decision to launch a $100 million public offering. The sharp decline deepens a broader downward trend for the company, which has seen its market value erode by roughly 31% over the last six months.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!